Consistent testing for EGFR, ALK, and ROS1 for patients with non‐squamous NSCLC reported by 100% of respondents (98% for BRAF) suggests familiarity with earlier approved treatments associated with those biomarkers regardless of practice setting, specialization, or other respondent characteristics. The gene discussed is ALK; the disease is non-small cell lung carcinoma.